Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
By Maggie Fick and Stine Jacobsen
LONDON/COPENHAGEN (Reuters) - Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.
Novo's rare disease unit head, Ludovic Helfgott, who was already on the executive management team, will immediately assume the responsibility for product and portfolio strategy, including commercial strategy, medical affairs and business development across all therapy areas, the company said.
Sylvest was one of two women on Novo's 10-person executive management team. Well known to investors and analysts, she was a consistent presence alongside Chief Executive Officer Lars Fruergaard Jorgensen, Chief Financial Officer Karsten Munk Knudsen, and others on earnings calls.
Novo's statement on Thursday said that Sylvest had decided to leave and did not cite a reason.
Another woman, Thilde Hummel Bøgebjerg, was promoted to the executive management team on Thursday, as executive vice president for Quality, IT & Environmental Affairs.
While some European pharmaceutical companies - including Swiss drugmakers Roche - have abandoned global diverse workforce targets in response to recent U.S. executive orders, Novo Nordisk says it remains committed to its DEI programmes.
(This story has been corrected to remove the reference to Novartis in paragraph 6)
(Reporting by Stine Jacobsen, editing by Terje Solsvik and Louise Heavens)
